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AbsTrACT
background Conjunctival defects can be repaired with 
several mucosal tissues. The simplicity of harvesting oral 
mucosa and its wide availability makes it the preferred 
graft tissue for all indications requiring mucosal grafting. 
Through analysing the postsurgical outcomes and rate of 
revisions, this study explores the suitability of oral mucosa 
grafts, depending on the initial diagnosis.
Methods We reviewed all the files of patients with a 
history of oral mucosal graft surgery, performed at our 
clinic between 2012 and 2018, focusing on complications 
and revision rates.
results In total, we analysed 173 oral mucosa grafts 
in 131 patients. The most common initial diagnosis was 
tumour resection, followed by surgical complications, 
postenucleation socket syndrome, trauma and ocular 
surface disorders. Complication and revision rates 
depended highly on the initial diagnosis. Revision rates 
were highest if the initial diagnosis included ocular surface 
disorders or chemical trauma.
Conclusions Oral mucosa grafting (OMG) is the most 
effective treatment for a wide range of ocular conditions 
involving conjunctival defects. Conjunctival defects that 
result from trauma or cicatricial surface diseases seem 
less suitable for OMG and may benefit from alternative 
graft tissue or treatment options.
InTroduCTIon
Mucosal grafting in periorbital reconstruc-
tion is a well- established surgical technique 
for the treatment of conjunctival deficien-
cies and scaring. The most commonly used 
mucosa types are oral, labial or nasal. Oral 
mucosa has similar biological properties to 
the conjunctiva. Both tissues consists of one 
or more layers of epithelial cells overlying a 
layer of loose connective tissue. Oral mucosa, 
however, is thicker and can be pigmented. It 
can be harvested repeatedly, and its donor 
site is easily accessible and is widely available. 
Donor site morbidity is low1 and the surgery is 
generally well tolerated by patients.2 In addi-
tion, the surgical technique is relatively easy, 
rendering oral mucosa an ideal candidate for 
the replacement of conjunctival defects.
Oral mucosal grafts have not only 
been used in the treatment of contracted 
sockets in anophthalmic patients3–7 and in 
ocular surface and fornix reconstruction 
in patients after tumour resection,8 9 but 
also in therapy refractive pterygia10 11 and 
in patients with ocular pemphigoid12 13 or 
symblephara.14 15 It is also the tissue that is 
most commonly used in the treatment of post-
surgical complications, including conjunctival 
insufficiencies after glaucoma,16 17 retinal 
surgery,18 keratoprothesis- related corneal 
melts19 20 and in lining the dacryocystorhi-
nostomy tract.21 In addition, buccal mucosa 
has been used for the repair of intractable 
sclerocorneal melts caused by serious chem-
ical burns.22
Compared with the oral mucosa, harvesting 
labial or nasal mucosa is more traumatic 
and can lead to more complications and 
discomfort.1 In contrast, nasal mucosa has 
the additional advantage of containing goblet 
cells that can increase the lubrication of the 
eye.23 Nasal mucosa grafting has shown good 
results in the treatment of severe mucus 
Key messages
What is already known about this subject?
 ► Conjunctival defects can be repaired with several 
mucosal tissues but the simplicity of harvesting oral 
mucosa and its availability makes it the preferred 
graft tissue.
What are the new findings?
 ► This study shows that good results can be obtained 
by using oral mucosa as the primary tissue for the 
reconstruction of conjunctiva independent of the 
reason for grafting.
How might these results change the focus of 
research and clinical practice?
 ► Mucosa grafting can be facilitated by choosing oral 
mucosa even in complex cases and other types of 
tissue might only be considered in rare instances.
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deficiency syndromes24 and labial tissue has successfully 
been used in patients with severe dry eye syndrome due 
to Stevens- Johnson syndrome or chemical burns.25 26
Besides mucosal tissues, the amniotic membrane is an 
alternative tissue that can be used in the ocular recon-
struction. The tissue has been used to cover defects 
after tumour excision15 27 28 but also in combination with 
oral mucosa grafting (OMG) in the treatment of severe 
symblephara.14 The use of amniotic membrane has the 
advantage of being less invasive and it has been suggested 
that due to the thinness of the membrane, monitoring 
tumour recurrence is facilitated.27 28Structural support of 
OMG, however, is higher and hence OMG can be used in 
a wider variety of indications.1
The simplicity of harvesting oral mucosa and its wide 
availability makes it the preferred graft tissue for all indi-
cations requiring mucosa grafting. Long- term outcomes, 
however, have been sparse and little is known about the 
suitability of this tissue when it is used in the treatment 
across different indications. Therefore, we exclusively 
performed oral mucosa grafts covering a broad spectrum 
of ophthalmological indications. Through analysing the 
postsurgical outcomes and rate of revisions, we are able to 
give clinically based recommendations for the suitability 
of oral mucosa grafts, depending on the initial diagnosis.
MeTHods
In this retrospective, observational study, we reviewed 
all files form patients with a history of oral mucosal graft 
surgery, performed at our clinic between 2012 and 2018. 
Cases were reviewed and details about the initial diag-
nosis, surgical procedure, complications and follow- up 
examinations were recorded. The follow- up of patients 
was passive via our outpatient clinic. This meant that 
patients had regular follow- up visits at least annually 
since the surgery and up to 5 years postsurgery.
All data were entered into a database and IBM SPSS 
statistics was used for data categorisation and analysis. We 
grouped similar diagnoses into larger categories to facili-
tate the analysis and presentation of data.
All patients received mucosal grafting performed 
by the same surgeons (E.B. or C.v.S.). As the surgery is 
performed under general anaesthesia, the endotracheal 
tube is placed on one side of the mouth to ensure a 
precise excision of oral mucosa on the other side (inner 
part of the cheek). The amount of oral mucosa required 
is estimated in accordance with the defect, taking into 
account a postoperative shrinking of the graft. The area 
of excision is chosen carefully to avoid damaging the 
parotid duct, which is normally located opposite the 
second upper molar. The area of excision is then marked 
with a surgical skin marker. Using local anaesthetic 
(Xylocitin 2%, Lidocaine+Epinephrin), the mucosa is 
infiltrated to facilitate the excision and reduce bleeding. 
A scalpel is used to incise the border of the previously 
marked mucosal graft, followed by the use of scissors to 
detach the graft completely. After careful haemostasis 
with bipolar coagulation forceps, the wound is closed 
with 5–0 Vicryl sutures. Finally, the oral mucosa graft is 
thinned out with scissors, paying careful attention not to 
perforate the graft and the oral mucosa is prepared to be 
transplanted to the required area.
Patient and public involvement
There was no patient involvement in planning and 
executing this study. We are planning to inform future 
patients when planning OMG surgeries and the public 
via the presentation of our findings on congresses and 
through publication.
resulTs
Between 2012 and 2018 we performed 173 mucosal graft 
surgeries in 74 men (56%) and 57 (44%) women, with a 
combined mean age of 57 years (SD 20 years). The mean 
follow- up time was 3.1 years (SD 2.2 years). Every patient 
had at least one follow- up visit approximately 1 year after 
the surgery. No patient was lost to follow- up immediately 
after surgery.
Figure 1 shows the primary diagnosis, indicating 
the need for mucosal graft surgery. Over half of all the 
patients were patients with tumour, with squamous cell 
carcinoma being the most common diagnosis (46%), 
followed by malignant melanoma (28%) and basalioma 
(6%). Rare diagnoses were carcinoma in situ, conjunc-
tival naevi, conjunctival melanosis, benign hyperplasia 
of the conjunctiva, adenocarcinoma and tumour of the 
caruncle. These patients were treated by removing the 
tumour, followed by mucosal grafting (figure 2). In 10 
cases, the excision of the tumour was combined with a 
corrective lid- surgery. Only in four cases, tumour size and 
location allowed for radiotherapy prior to tumour exci-
sion.
The second most frequent diagnosis that required 
mucosal graft surgery was surgical complications. Here, 
the most frequent surgery that required correction 
by mucosal grafting was a pterygium surgery (6, 33%), 
either because of recurrence or because of symblephara. 
Accordingly, patients were treated with surgical excision 
or symblepharolysis with mucosal grafting (figure 3). The 
second most common surgery requiring mucosal grafting 
was trabeculectomy (4, 22%). Two patients with tenon’s 
cysts were treated by removing the cyst and mucosal 
patching and in two other patients, conjunctival insuffi-
ciencies were patched with mucosal grafts. Furthermore, 
conjunctival defects due to prior surgery were seen in 
patients with, Ahmed valve (4), after pars plana vitrec-
tomy (2), after radiation (1) and after lid surgery (1). All 
patients were successfully treated with mucosal grafting.
Equally frequent was a patient who had undergone 
enucleation. In 10 cases, patients had undergone 
enucleation due to phthisis bulbi, in 4 patients enucle-
ation was performed due to uncontrollable secondary 
glaucoma and in 3 cases enucleation followed a severe 
trauma. None of the cases had a history of ocular 
tumours. In the majority of cases, we performed a 
fornix reconstruction with mucosal graft or OMG—fat 
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Figure 1 Frequency of OMG surgery by the initial diagnosis. OMG, oral mucosa grafting.
Figure 2 Patient with benign conjunctival hyperplasia 5 years after removal and patching with OMG. OMG, oral mucosa 
grafting.
graft to treat orbital volume deficits. In three patients, 
who had undergone enucleation due to a trauma, we 
performed a symblepharolysis with fornix reconstruc-
tion and mucosal grafting.
In patients who had suffered injuries, we performed 
mucosal grafting to treat four patients with acid 
burns, four patients with heat burns and two patients 
after explosive trauma. All patients were treated with 
symblepharolysis or fornix reconstruction and mucosal 
grafting.
Patients with cicatricial ocular surface disease consisted 
of four patients with ocular pemphigoid, two patients 
with Stevens- Johnson syndrome and one patient with 
Lyell syndrome. Two patients with ocular pemphigoid 
received mucosal grafting as part of a keratoprothesis. 
In the other two patients as well as in the patients with 
Stevens- Johnson syndrome, extensive symblephara were 
removed and patched with mucosal grafts (figure 4). 
One patient with Lyell syndrome showed pronounced 
atrophy of the conjunctiva and it was replaced with a 
mucosal graft.
Mucosal grafting was also used to treat the less common 
diagnosis. We treated three patients with congenital or 
post- traumatic lid deformities that had led to an atrophy 
of the conjunctiva because of insufficient lid closure. In 
one case, the removal of a conjunctival foreign body left 
a defect that had to be patched with oral mucosa and two 
cases of scleromalacia of unknown origin as well as one 
patient with a tear duct fistula were successfully treated 
with mucosal grafting (figure 5).
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Figure 3 Therapy refractive pterygium patched with OMG. OMG, oral mucosa grafting.
Figure 4 Fornixreconstruction with OMG in Steven- Johnson syndrome. OMG, oral mucosa grafting.
Complications
The most common complication was symblephara. 
Symblephara developed in 66% of all surgeries, in 
patients with cicatricial ocular surface diseases, in 41% 
of all surgeries in patients that had sustained injuries, in 
33% of all surgeries in postenucleation patients, and in 
20% of all surgeries in patients with tumour.
Graft overgrowth occurred nine times but only in 
patients with tumour. These cases were monitored more 
frequently to assure that the overgrowth was not due to a 
tumour recurrence. In one case, overgrowth was surgically 
removed and tumour recurrence excluded by pathological 
analysis. None of the cases with overgrowth were due to 
tumour recurrence. Graft necrosis was observed only once.
revisions
The majority of patients were successfully treated with a 
single surgery. None of the revision surgeries were due to 
cosmetic dissatisfaction. In 31 cases (24%), a revision was 
required and among these cases, 7 patients had to undergo 
multiple revisions. Table 1 shows the frequency of revisions 
stratified by the initial diagnosis. Revision rates were highest 
in patients suffering from cicatricial ocular surface diseases, 
with almost every other patient requiring more than one 
surgery to remove symblephara. Similarly, almost half of all 
postenucleation patients required more than one surgery 
in order to successfully reconstruct the orbital socket. 
Revisions were required in one case due to, mucosal graft 
insufficiency, insufficient fornix reconstruction or to treat 
a postenucleation syndrome. Multiple revisions, however, 
were only observed if the patient was anophthalmic due to 
trauma (explosion or acid burns) or if the patient had an 
underlying surface disease (Sjörgen syndrome). Among 
patients with tumour, five patients underwent more than 
one surgery due to a tumour recurrence. In none of the 
cases, tumour recurrence occurred underneath the graft. 
Tumour recurrence did not depend on the type or size 
of the primary tumour or on prior radiotherapy (data 
not shown). Besides tumour recurrence postsurgical 
symblephara that led to the reconstruction of the fornix 
was another reason for additional surgery among patients 
after tumour resection. Multiple revisions, however, were 
seen only in patients with and due to tumour recurrence.
In the group of patients with postsurgical compli-
cations, revisions were required to treat, further 
conjunctival insufficiencies, recurrence of a tenon’s cyst 
and to remove symblephara.
dIsCussIon
Autologous oral mucosal grafts are a viable option for 
the treatment of various ocular surface and lid disorders. 
In addition, OMG can be used to treat a broad range 
of postsurgical complications involving defects of the 
conjunctiva. The rate of complications is generally low, 
although a higher rate of revisions is required in patients 
with cicatricial ocular surface diseases.
In our clinic, the most common indication for OMG 
was ocular surface and fornix reconstruction in patients 
after tumour resection, and in particular, squamous cell 
carcinoma and malignant melanoma. Although basal cell 
carcinoma is the most common tumour of the eyelid, it 
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Figure 5 Scleromalacia of unknown origin patched with OMG. OMG, oral mucosa grafting.
Table 1 Revision rates stratified by initial diagnosis
Diagnosis One revision >1 revision
Enucleation 5 (29%) 3 (17%)
Cicatricial ocular surface diseases 3 (43%) 1 (15%)
Trauma 2 (30%) 0
Other 1 (10%) 0
Surgical complications 2 (11%) 0
Tumour 11 (15%) 3 (4%)
rarely requires OMG if the eyelid can be reconstructed 
without large damage to the conjunctiva. In contrast, 
we generally combine resection of conjunctival tumours 
with OMG. Our experience shows that although the abso-
lute number of complications was highest in this group 
of patients, the relative rate was considerably lower than 
in patients with cicatricial surfaces diseases or postenu-
cleation socket syndrome. The latter could be due to 
the fact that conjunctival defects as a result of tumour 
resection are, with the exception of a very large tumour, 
smaller in size which could facilitate healing and reduce 
complications. The most common complication in OMG 
after tumour resection was symblephara, which occurred 
in almost every fifth patient, although most of them did 
not require revision surgery. In fact, the most common 
reason for revision surgery in this group of patients was 
a tumour recurrence. In the absence of tumour recur-
rence, OMG did not require a revision procedure.
When considering tumour recurrence in the usage of 
OMG, one has to consider the possibility that recurrence 
can occur underneath the graft. In such cases, due to the 
thickness of the graft, OMG could conceal a tumour and 
noticing tumour recurrence is delayed.27 28 In this study, 
we did not compare OMG with other, thinner tissues such 
as amniotic membrane and hence cannot comment on a 
possible delay in diagnosis. The low rate of tumour recur-
rence and the absence of tumour recurrence underneath 
the graft, however, suggest that OMG is a safe method after 
tumour excision.
The second most common indication for OMG in this 
study was surgery- related complications. Pterygium is 
known to recur even after conjunctival autografting in up 
to 47% of cases10 and it was the most common indication 
for OMG in the group of surgery- related complications. 
In this study, we did not see any recurrence after OMG 
grafting, similar to Trivedi et al showing no pterygium 
recurrence after treating 140 cases with OMG.29
The treatment of conjunctival deficiencies as a result 
of complex glaucoma surgery can also successfully be 
treated using OMG.1 A leaking trabeculectomy bleb can 
be a complication of trabeculectomy and it has been 
successfully reconstructed using OMG.16 In this study, we 
show positive results when using OMG in the treatment 
of leaking blebs and in patients treated for tenon’s cysts 
as a result of trabeculectomy. In these patients, the cyst 
was removed, and the bleb was successfully reconstructed 
using OMG, which required a revision in only one case.
The implantation of a glaucoma aqueous drainage 
device can lead to conjunctival deficiencies or even 
erosions.17 Rootman et al used a combination of lamellar 
corneal grafts covered with OMG to repair the defects.17 
Due to its simplicity, we prefer OMG grafting to patch 
small conjunctival deficiencies, which repaired all defects 
successfully and required only one revision procedure. 
This suggests that simple OMG is an adequate technique 
for the treatment of such complications.
Besides glaucoma surgery, OMG can also be useful in 
the treatment of complications associated with retinal 
surgery. OMG has been used to manage exposed silicone 
retinal explants,18 a complication not seen in this study. 
We used OMG only in patients with scarred conjunctiva 
resulting from multiple retinal procedures. OMG was 
suitable for the patching of the conjunctival defects and 
no revisions were required.
Postenucleation socket syndrome with orbital volume 
deficit has been treated with dermis fat graft alone 
or in combination with OMG.30 Dermis fat grafting is 
frequently used in our clinic to fill up ocular volume 
deficiency and additionally to achieve deeper fornices in 
cases of symblephara. Our experience shows that dermis 
fat grafting alone was most effective with regard to an 
adequate compensation of the volume deficit but that in 
more complex postenucleation socket syndromes with 
pronounced symblephara, a revision surgery was required 
because of insufficient fornix depth. This could indicate 
that more complex postenucleation syndromes might be 
best treated using a two- step procedure, consisting of a 
Berlin, M
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replacement of the volume deficit, followed by a second 
surgery using OMG to reconstruct the fornix.
Insufficient conjunctival fornix depth and postenu-
cleation socket syndrome are common in anophthalmic 
patients, impairing the adequate position of prosthesis.31 
Increasing the depth of the inferior fornix, thereby 
augmenting the conjunctival surface area can be achieved 
with OMG31 and this can improve the fit of the prosthesis.5 
We used this procedure successfully in patients with inad-
equate fornix depth, who presented themselves because 
of an ill- fitting prosthesis. Revisions due to inadequate 
fornix depth were only required in two cases. Nevertheless, 
if fornix reconstruction had to be performed on anoph-
thalmic patients who had suffered from trauma, the revision 
rate was considerably higher and various subsequent proce-
dures were required. In fact, revision rates in these patients 
were similar to revision rates seen in patients with cicatri-
cial ocular surface disease. This could indicate that OMG in 
patients with symblephara as a result of trauma has a worse 
prognosis. Using nasal tissue could be more suitable for 
this group of patients.23 Supposedly, nasal mucosa contains 
goblet cells that add to the lubrication of the eye, which 
could impede the development of new symblephara.
Similar to what was seen in patients with symblephara due 
to trauma, conditions that lead to extensive symblephara 
may have a worsened prognosis after OMG. We performed 
symbelpharolysis in patients with ocular pemphigoid 
and Steven- Johnson syndrome. These groups of patients 
required more revisions than any other group and they 
had the highest rate of postoperative symblephara. After 
reviewing long- term results, Heiligenhausen et al, concluded 
that OMG should not be performed in patients with severe 
ocular pemphigoid.12 The postoperative outcome seen 
in this study also suggests that oral tissue might not be an 
adequate graft material in patients with ocular pemphi-
goid. We assume that a lack of lubrication contributed to 
the higher revision rate. Again, using a tissue with a mucine 
production such as nasal mucosa24 or labial salivary gland 
transplantation25 could reduce revision rate and might lead 
to better outcomes.
In conclusion, OMG is the most effective treatment for 
a wide range of ocular conditions involving conjunctival 
defects. OMG after tumour resection or prior to surgical 
intervention has few postoperative complications and 
seldom requires revision procedures. Similarly, OMG revi-
sion rates are low when used in the process of a fornix 
reconstruction in patients with postenucleation socket 
syndrome. In contrast, conjunctival defects as a result of 
trauma or cicatricial surface diseases seem less suitable for 
OMG. Here, alternative graft tissue or treatment options 
should be considered.
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